Tag: Keytruda
Cancer: Merck halts late phase study combining Keytruda with Eisai’s Lenvima – 08/25/2023 at 14:52
(AOF) – Merck and its partner Eisai announced on Friday their decision to end an advanced phase study testing an experimental combination therapy for head and neck cancer, after an…
Merck and co inc: Success with Keytruda in pleural cancer
Receive daily value for free every morning The data collected is essential for this processing and is intended for the relevant departments of BFM Bourse and, where applicable, its service…
Merck and co inc: Two phase 3 failures for Keytruda
Receive daily value for free every morning The data collected is essential for this processing and is intended for the relevant departments of BFM Bourse and, where applicable, its service…
Merck and co inc: Four new approvals for Keytruda in Japan
Read also (CercleFinance.com) – Merck announced today that Keytruda has been approved by Japanese health authorities for four new indications. Merck’s anti-PD-1 therapy, Keytruda, is now approved when combined with…
Merck and co inc: Double failure for Keytruda in phase 3 trials
Receive the value of the day selected by The data collected is essential for this processing and is intended for the relevant departments of BFM Bourse and, where applicable, its…
Pfizer: Positive CHMP opinion for KEYTRUDA
Receive the value of the day selected by The data collected is essential for this processing and is intended for the relevant departments of BFM Bourse and, where applicable, its…
Merck: positive CHMP opinion for KEYTRUDA
(CercleFinance.com) – Merck has announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has adopted a positive opinion recommending the approval of KEYTRUDA.…
Merck and co inc: Failure of a clinical trial on Keytruda
Receive the value of the day selected by The data collected is essential for this processing and is intended for the relevant departments of BFM Bourse and, where applicable, its…
Merck and co inc: EU approves Keytruda for kidney cancer
Receive the value of the day selected by The data collected is essential for this processing and is intended for the relevant departments of BFM Bourse and, where applicable, its…
Merck: EU approves Keytruda for kidney cancer
Merck advises that the European Commission has approved Keytruda as monotherapy for the adjuvant treatment of adults with renal cell carcinoma (RCC) at increased risk of recurrence after nephrectomy, or…